Brokers Offer Predictions for VIR Q1 Earnings

Vir Biotechnology, Inc. (NASDAQ:VIR) – Equities researchers at HC Wainwright issued their Q1 2026 earnings estimates for shares of Vir Biotechnology in a research note issued on Friday, February 28th. HC Wainwright analyst P. Trucchio anticipates that the company will earn ($0.80) per share for the quarter. HC Wainwright has a “Buy” rating and a $110.00 price objective on the stock. The consensus estimate for Vir Biotechnology’s current full-year earnings is ($3.92) per share. HC Wainwright also issued estimates for Vir Biotechnology’s Q2 2026 earnings at ($0.80) EPS, Q3 2026 earnings at ($0.81) EPS and Q4 2026 earnings at ($0.77) EPS.

A number of other equities research analysts have also recently weighed in on VIR. JPMorgan Chase & Co. upped their price objective on Vir Biotechnology from $10.00 to $14.00 and gave the stock a “neutral” rating in a research note on Thursday, January 9th. Leerink Partners increased their price target on shares of Vir Biotechnology from $18.00 to $20.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Vir Biotechnology in a research report on Thursday, February 27th. Barclays boosted their price objective on shares of Vir Biotechnology from $26.00 to $31.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, Morgan Stanley upgraded shares of Vir Biotechnology from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $10.00 to $20.00 in a research note on Thursday, January 9th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $35.67.

Vir Biotechnology Trading Down 5.6 %

Shares of Vir Biotechnology stock opened at $7.92 on Monday. Vir Biotechnology has a 12 month low of $6.56 and a 12 month high of $14.45. The stock’s fifty day moving average price is $9.47 and its 200-day moving average price is $8.49. The firm has a market cap of $1.09 billion, a P/E ratio of -2.02 and a beta of 0.64.

Vir Biotechnology (NASDAQ:VIR) last issued its earnings results on Wednesday, February 26th. The company reported ($0.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.09. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The business had revenue of $12.37 million during the quarter, compared to analyst estimates of $8.14 million.

Insider Activity at Vir Biotechnology

In other news, Director Vicki L. Sato sold 10,960 shares of the company’s stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $12.52, for a total value of $137,219.20. Following the completion of the sale, the director now directly owns 1,312,391 shares in the company, valued at $16,431,135.32. This represents a 0.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Verneuil Vanina De sold 7,373 shares of the firm’s stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $9.14, for a total value of $67,389.22. Following the completion of the sale, the executive vice president now directly owns 79,460 shares of the company’s stock, valued at $726,264.40. This trade represents a 8.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,859 shares of company stock valued at $326,458. 15.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of VIR. Blue Trust Inc. grew its stake in shares of Vir Biotechnology by 143.5% in the third quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock valued at $30,000 after buying an additional 2,351 shares in the last quarter. Victory Capital Management Inc. boosted its stake in Vir Biotechnology by 23.9% in the third quarter. Victory Capital Management Inc. now owns 81,269 shares of the company’s stock valued at $609,000 after acquiring an additional 15,696 shares in the last quarter. Quest Partners LLC boosted its stake in Vir Biotechnology by 171.4% in the third quarter. Quest Partners LLC now owns 34,455 shares of the company’s stock valued at $258,000 after acquiring an additional 21,760 shares in the last quarter. Intech Investment Management LLC purchased a new stake in Vir Biotechnology in the third quarter valued at approximately $191,000. Finally, Charles Schwab Investment Management Inc. grew its position in Vir Biotechnology by 13.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,134,276 shares of the company’s stock worth $8,496,000 after purchasing an additional 136,087 shares during the last quarter. Hedge funds and other institutional investors own 65.32% of the company’s stock.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).